drugset / Trial / NCT05390515
Psoriatic Immune Response to Tildrakizumab
Phase 4
Recruiting
10 enrolled
University of California, San Francisco
Sun Pharmaceutical Industries, Inc. · collab
NaSingle-groupOpen-labelBasic science
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2028-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tildrakizumab | Monoclonal antibody | — | — |